RecruitingNCT07786077
A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
Patients' Preferences for Primary Immune Thrombocytopenia Treatment
Sponsor
Novartis Pharmaceuticals
Enrollment
100 participants
Start Date
Dec 8, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to evaluate treatment preferences of patients with Primary Immune Thrombocytopenia (ITP) in the United States (US) by conducting a preference elicitation survey.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with primary immune thrombocytopenia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07786077
Related Trials
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
NCT07700238
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
NCT077102485 locations
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
NCT0703942225 locations
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
NCT0507084531 locations
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT061075821 location